Pfizer's zero-buyback posture remains a useful contrast against AI and Berkshire capital allocation. [1][2]

No Sunday update changed the disciplined-cohort anchor. MSM files pharma earnings separately; X ignores the restraint. The paper's discipline is to publish the artifact and the caveat together, not to inflate a watch item into a verdict.

The brief stays narrow by design. It names the public record, the missing follow-up, and the specific receipt that would turn this watch item into a fuller story. That lets readers distinguish a live thread from a completed claim without pretending Sunday's evidence says more than it does.

The restraint is intentional, but it is not absence. The item gives tomorrow's editor a named place to look: a filing page, a league schedule, a public-health table, a broadcaster statement, a market open, or a government response. If that record appears, the brief becomes a follow-up. If it does not, the silence remains part of the paper's memory rather than disappearing into the feed.

That narrow watch is useful because it prevents tomorrow's newsroom from rebuilding context from scratch.

The point is continuity, not volume, and the receipt is now named for the next pass.

-- THEO KAPLAN, San Francisco